News | August 22, 2013

Real-time Assessment of Tumor Response Presentation Wins Innovation Competition

Award goes to Dr. Kai Chen at the 2013 SNMMI meeting

August 22, 2013 — Molecular Targeting Technologies Inc. (MTTI) announced Dr. Kai Chen of the University of Southern California was awarded the 2013 Center for Molecular Imaging Innovation and Translation (CMIIT) Young Investigator Award during the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver, Canada. Chen presented results from his study entitled: “Synthesis and evaluation of a novel bis (zinc(II)-dipicolyamine) derivative for dual-modality PET/NIRF (positron emission tomography/near-infrared flourescence) imaging of phosphatidylserine exposure.”

This real-time assessment probe can be used to monitor tumor response in as early as one day to evaluate treatment efficacy and intervene early in treatment modification. Non-invasive imaging of drug response has a significant clinical impact and can be broadly useful for monitoring numerous conditions, including cancer, cardiovascular diseases, neurology and renal diseases.

Chen, assistant professor of the department of radiology at USC said, “Novel tools to assist in the non-invasive, real-time assessment of tumor response to anti-cancer treatment are urgently needed. Our current preclinical results could lead to a robust imaging agent, offering synergistic advantages, not only to allow comprehensive collection of cell death information, but also to facilitate clinical applications of image-guided surgery.”

For more information: mic.usc.edu, www.mtarget.com

Related Content

Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
Icon Launches New Clinical Trial Patient Engagement Platform
Technology | Patient Engagement | May 14, 2019
Icon plc announced the release of its web-based clinical trial patient engagement platform, to provide patients with...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...